ArticlePediatric transplantation2025
Semilunar Valve Function After Rejection in Heart Transplant Recipients: Implications for Partial Heart Transplantation.
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Semilunar Valve Function After Rejection in Heart Transplant Recipients: Implications for Partial Heart Transplantation.Pediatric transplantation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPartial heart transplantation (PHT) is a promising procedure for pediatric patients with irreparable semilunar valve disease. Current immunosuppression regimens mirror orthotopic heart transplant (OHT) protocols. However, semilunar valves may have immune privilege, making true immunosuppressive requirements unclear. This study examines the effect of rejection on semilunar valves in OHT to inform immunosuppression strategies for PHT.
methodsWe conducted a single-center retrospective case-control study of pediatric OHT recipients from 2008 to 2023. Patients were grouped by the presence or absence of rejection episodes, with further stratification by rejection severity. Semilunar valve function was assessed via echocardiography at baseline, during, and after rejection episodes. Subgroup analysis was performed based on rejection severity and age at transplant (< 1 year of age).
resultsOf 113 eligible OHT recipients, 57 had ≥ 1 rejection episodes (32 high-grade). Baseline valve function was comparable between rejection and non-rejection groups. After a 3.8-year median follow-up, there were no significant differences in aortic or pulmonary valve gradients or in the prevalence of clinically significant regurgitation between groups. Paired analysis during rejection demonstrated no change in valve function compared to pre-rejection assessment. Similar findings were observed in infants transplanted < 1 year of age.
conclusionsOver a median follow up of nearly 4 years, semilunar valve function in pediatric OHT recipients remained clinically unaffected by rejection, even in high-grade cases and among younger patients. These findings support the hypothesis of semilunar valve immune privilege and suggest that intensive immunosuppression may not be necessary to preserve valve function after PHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.